Precision oncology is an approach to cancer treatment that tailors therapy to the specific molecular features of a patient’s tumor rather than relying only on its tissue of origin or stage. It is driven by advances in genomics, bioinformatics and targeted drug development.

A central element is comprehensive molecular profiling. Using next generation sequencing, tumors are analyzed for mutations, copy number changes, gene fusions, epigenetic changes and sometimes RNA expression. These data identify “driver” alterations that sustain cancer growth, such as mutations in EGFR, BRAF, ALK or HER2. When matched to targeted drugs, these alterations can guide highly specific therapies that are often more effective and less toxic than conventional chemotherapy.

Clinical implementation uses different trial designs. Basket trials group patients by shared molecular alteration across tumor types, while umbrella trials test multiple targeted therapies within a single cancer type based on distinct genomic profiles. Large scale programs have shown that a substantial fraction of patients harbor actionable alterations, but only a subset ultimately receive genomically matched therapies due to clinical, logistical or regulatory barriers.

Despite important successes in diseases such as lung cancer, melanoma and certain leukemias, challenges remain. Tumor heterogeneity and clonal evolution can lead to resistance, requiring repeat biopsies or liquid biopsies that analyze circulating tumor DNA. Not all genomic alterations have corresponding drugs, and many rare variants lack clear biological interpretation.

Ongoing research integrates genomics with transcriptomics, proteomics and immune profiling, and explores combinations of targeted agents and immunotherapies. The long term aim is to convert cancer into a more controllable, chronic condition through precisely guided, adaptable treatment strategies.